Tag: GlobeNewswire

MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability testing, supporting preparations for the planned Phase 1b, First-In-Human study of the Company’s lead clinical candidate, PPC-001, in up to 50 advanced cancer patients with solid tumors.

“Propanc continues to advance its analytical development activities in parallel with preparations for its Phase 1b First-In-Human study,” said Dr. Ralf Brandt, Propanc’s Research & Development Director. “The ongoing feasibility assessment of immunogenicity assays, together with the planned optimization of pharmacokinetic bioanalytical methods and stability testing, represents an important component of the Company’s clinical development strategy.”

Key achievements include:

• Encouraging stability results for PPC-001 in human blood matrices: Bioanalytical studies demonstrated that the two proenzyme components of PPC-001, trypsinogen and chymotrypsinogen, remained detectable without evidence of significant degradation over the investigated sample-handling periods.
• Stability demonstrated across three human donors: Follow-up experiments conducted by FyoniBio evaluated serum and plasma samples from three individual donors, strengthening the initial feasibility findings.
• Stability over 60 minutes at room temperature: The September study demonstrated recovery results generally exceeding 85% after 60 minutes, supporting the feasibility of clinical blood sample collection and processing procedures.
• Successful application of mass spectrometry: LC-MS-based analytical methods were used to measure both proenzyme components in human serum and plasma, providing a foundation for further development of pharmacokinetic assays.
• Progress in immunogenicity assay development: Laboratory experiments demonstrated successful preparation of biotin- and sulfoTAG-labelled trypsinogen and chymotrypsinogen reagents, with no degradation observed by SDS-PAGE under the tested labelling conditions.
• Additional evidence of short-term reagent stability: Labelled assay reagents showed no detectable degradation by SDS-PAGE following storage for one day at 4°C under the tested conditions, supporting continued development of anti-drug antibody (ADA) assays.

Advancement toward clinical bioanalytical readiness – together, these findings support continued assay optimization and pre-validation activities required for the planned clinical development of PPC-001 and are structured in the three key areas based on the unique properties of treatment. These activities are expected to provide the analytical foundation required to support the evaluation of PPC-001 during its clinical development program.

1. Anti-Drug Antibody Assay Development: The feasibility assessment for the development of two ADA assays, targeting the individual proenzyme components trypsinogen and chymotrypsinogen, is currently underway. The feasibility program is evaluating the suitability of existing positive control antibodies to support the development of reliable immunogenicity assays. Following successful feasibility assessment, the program is scheduled to progress to assay establishment and subsequent validation.
2. Pharmacokinetic Bioanalytical Method Development: The Company has established a structured analytical development program aimed at optimizing the sensitivity and performance of bioanalytical methods for measuring PPC-001 components in clinical samples. The program includes the evaluation of stable isotope-labelled peptides as internal standards, strategies to minimize biological matrix effects, and optimization of sample volumes to improve analytical sensitivity. Additional activities will focus on reducing sample analysis time and establishing a suitable analytical method for subsequent clinical application.
3. Stability Assessment and Analytical Support: Stability testing activities covering the drug product and its analytical characteristics are included in the development program. The analytical program is intended to generate the data necessary to support appropriate sample handling, analytical reliability and clinical bioanalytical assessments.

“The work undertaken led by Dr Ralf Brandt, our R&D Director, his team, and our partner CRO is of a high standard and provides an excellent framework for our world-first study for PPC-001 in advanced cancer patients,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “PPC-001, a combination therapy consisting of two pancreatic proenzymes from naturally derived sources is a unique approach to cancer treatment which has the capacity to reverse the effects of cancer cell dissemination and recurrence. By undertaking these important bioanalytical activities, we are going to obtain great insight into the effects of PPC-001.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN

TORONTO and HAIFA, Israel, Oct. 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued development of its lead therapeutic candidate, ExoPTEN.

Anti-inflammatory activity is a key biological property attracting interest in exosomes for applications ranging from skin health to tissue repair. NurExone’s latest results showed that three separately produced batches demonstrated similar and substantial anti-inflammatory activity. Two key proteins involved in inflammation, IL-6 and TNF-α, showed average reductions of approximately 88% and 57%, respectively. This anti-inflammatory activity shown in the laboratory supports the potential of NurExone’s exosomes for clinical applications where controlling inflammation is relevant to tissue protection, repair and regeneration.

“The anti-inflammatory properties of our exosomes have potential relevance for both our therapeutic development and commercial strategy,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “For ExoPTEN, these findings support the exosome component of our approach to acute spinal cord and optic nerve injuries. For Exo-Top, they provide additional evidence of product consistency as we begin manufacturing and work toward supplying naïve exosomes for applications such as skin and tissue care. Addressing batch-to-batch consistency, a critical unmet challenge in the exosome field, helps distinguish the quality and reliability we expect to bring to the exosome market.”

“Manufacturing biological drug substances is an exceptionally complex process governed by strict Chemistry, Manufacturing and Controls (“CMC”) regulatory requirements,” said Dr. Tali Kizhner, Director of Research and Development at NurExone. “As part of our CMC program for ExoPTEN, we have we have generated data regarding the physical characteristics and the composition of our exosomes, and now in their anti-inflammatory activity across production batches. This rigorous approach also supports the quality and reliability of the naïve exosomes we plan to supply commercially through Exo-Top.”

These achievements provide further positive support for the Company’s manufacturing foundation as it advances its U.S. production strategy in collaboration with Made Scientific, with a focus on scalability, consistent product characteristics and reproducible biological activity.

About the Study

Researchers evaluated the anti-inflammatory activity of three batches of NurExone’s bone marrow-derived mesenchymal stromal cell extracellular vesicles (BM-MSC EVs) using RAW 264.7 macrophages, a laboratory cell model commonly used to study inflammatory responses.

The macrophages were stimulated with lipopolysaccharide (LPS) to induce the secretion of pro-inflammatory cytokines. Cells were then treated with increasing concentrations of NurExone EVs. IL-6 and TNF-α levels in the culture supernatants were measured and expressed as percentages of the LPS-stimulated control, with dexamethasone included as a positive control.

All three tested batches showed dose-dependent suppression of IL-6 and TNF-α. At the highest EV concentration, average cytokine reductions reached approximately 88% and 57%, respectively, relative to the LPS-stimulated control.

The overall dose-response patterns were similar across batches, although some variability was observed, particularly for TNF-α at intermediate concentrations. These findings support batch-to-batch consistency of the measured biological activity.

Figure 1. Reproducibility of anti-inflammatory activity across three production batches of NurExone BM-MSC extracellular vesicles.

(A) IL-6 suppression and (B) TNF-α suppression in LPS-stimulated RAW 264.7 macrophages treated with increasing concentrations of NurExone EVs. Cytokine concentrations in culture supernatants are expressed as percentages of the LPS-stimulated control (mean ± standard deviation). Each dot represents the mean response of a different production batch (three batches in total, N=3). Dexamethasone was included as a positive control.

All three batches demonstrated similar dose-dependent anti-inflammatory responses, with relatively small variation at the highest concentrations tested. Average reductions reached approximately 88% for IL-6 and 57% for TNF-α at the highest concentration. Despite some variation at intermediate concentrations, particularly for TNF-α, the results demonstrated consistent biological activity across the three production batches. These in-vitro findings do not establish clinical anti-inflammatory efficacy.

About NurExone

NurExone is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation from the U.S. FDA and European EMA, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company aims to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, X (formerly Twitter), Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are based on expectations, estimates and projections as of the date of this press release and are generally identifiable by words such as “may,” “will,” “could,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “potential,” “continue,” “advance” and similar expressions.

Forward-looking statements in this press release include statements concerning: the potential for the reported in-vitro results to support the continued development of ExoPTEN and the Company’s proposed commercial supply of naïve exosomes through Exo-Top; the potential relevance of the Company’s exosomes to tissue protection, repair and regeneration and to skin and tissue-care applications; the potential for the Company to achieve reproducible biological activity and batch-to-batch consistency in future production; the advancement of the Company’s U.S. production strategy and its collaboration with Made Scientific; the Company’s plans to manufacture and supply naïve exosomes commercially; and the Company’s broader development, manufacturing, regulatory, clinical and commercialization plans for ExoPTEN and other exosome-based products.

These forward-looking statements are based on material assumptions including that: the reported laboratory data and the Company’s interpretation of those data are accurate and complete; the three tested batches and the in-vitro RAW 264.7 macrophage model provide information relevant to the measured biological activity; the reported dose-response patterns and cytokine reductions can be reproduced in additional batches, at larger scale and under future manufacturing conditions; the Company will be able to further develop, validate and scale its manufacturing processes and meet applicable quality, regulatory and manufacturing requirements; arrangements with Made Scientific and other collaborators will progress as contemplated; sufficient funding, materials, facilities, personnel and collaborators will be available on acceptable terms; demand for naïve exosomes will develop; and the Company will be able to advance ExoPTEN, Exo-Top and its other programs as currently contemplated.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially, including: the preliminary, limited and in-vitro nature of the reported results; the use of only three production batches and the variability observed at certain concentrations; the risk that the results will not be reproduced in additional batches, different assays, larger-scale production, animal studies or human studies; the risk that reduction of IL-6 or TNF-α in the reported model will not translate into clinical efficacy, safety, product quality, regulatory acceptance or commercial utility; variability inherent in biological materials and exosome manufacturing; process-development, scale-up, validation, contamination, quality-control, supply-chain, facility, equipment and personnel risks; the need for additional research, testing, technology transfer and regulatory work; the inability to obtain sufficient financing, materials, facilities, personnel, collaborators, customers or commercial orders; delays, changes or termination affecting the Company’s collaboration with Made Scientific or other counterparties; competition, technological change, intellectual-property risks and the absence of sufficient market demand; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s annual information form dated August 27, 2024 and other continuous disclosure documents available under the Company’s SEDAR+ profile, copies of which are available under the Company’s SEDAR+ profile at www.sedarplus.ca.

The laboratory results described in this press release are preclinical and in-vitro, are based on three production batches and do not establish clinical anti-inflammatory efficacy, safety in humans, commercial-scale manufacturing capability, regulatory compliance, product approval or commercial demand. ExoPTEN is an investigational product candidate, has not been approved for commercial use or for the treatment of any condition by any regulatory authority, and its safety and efficacy in humans have not been established. No assurance can be given that the Company will successfully scale or reproduce the reported results, obtain regulatory authorization, enter into commercial supply arrangements or generate revenue from Exo-Top. Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable, there can be no assurance that the anticipated activities, benefits, demand or results will occur or be achieved. Readers should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of this press release, and the Company disclaims any obligation to update or revise them except as required by applicable law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f7960f2-727f-4683-8241-85515243707c

CHONGQING, China, Oct. 30, 2026 (GLOBE NEWSWIRE) — On October 30, SERES announced its financial results for the third quarter of 2026. Revenue for the quarter reached RMB 28.08 billion, and net profit attributable to shareholders of the listed company came to RMB 1.42 billion, marking a return to profitability.

High-end Lineup Keeps Expanding; AITO M9 Maintains Lead Above RMB 500,000

Since the beginning of this year, AITO’s product range has continued to expand, and its products have further realised their high-end value. Deliveries of the AITO M9 Ultimate have begun. The AITO M9 has been the best-selling model priced above RMB 500,000 for four consecutive months, and cumulative deliveries of the AITO M6 have passed 60,000 units. The new AITO M8, upgraded across six key areas of the ownership experience, will go on sale on November 13, and the company is set to enter a new, strong product cycle.

In Brand Finance’s Automobiles 100 2026 ranking, AITO placed first among Chinese luxury automotive brands with a brand value of USD 3.448 billion. AITO recently showcased the AITO M9, M8, M7 and M6, together with the SERES MF Platform and its latest technologies, at the 2026 Paris Motor Show. It also announced its entry into the European market in autumn 2027, which is an important step in the brand’s global expansion.

Buybacks and Share Purchases Signal Confidence; Boosting Investor Confidence Through Action

SERES has increased both the scale and the intensity of its R&D investment. Its platform-based architecture and reuse of hardware and software modules further strengthen its core competitiveness. In-house developments including the SERES MF Platform 2.0, the new-generation Super Range Extender System and its intelligent safety system have entered rollout, and the company is expanding into new areas such as embodied intelligence.

In the capital markets, SERES has also moved to strengthen investor confidence. Year to date, the company has repurchased 17.5357 million shares for about RMB 983 million in total. Directors, senior executives and core team members have completed a RMB 148 million plan to buy A-shares and H-shares, and a purchase plan by the controlling shareholder is under way.

Market analysts note that ramping sales of high-end models and a broader product lineup are adding new growth momentum. Combined with steady progress in overseas expansion and new businesses, this points to stronger earnings elasticity and growing room for growth in Q4.

About SERES Group

Founded in 1986, SERES is a technology-driven company with new energy vehicles (NEVs) at the core of its business. Listed in Shanghai and Hong Kong, SERES is also recognized among China’s Top 500 Enterprises. The company specializes in the R&D, manufacturing, sales and service of new energy vehicles, as well as core electric powertrain technologies.

The name SERES is derived from the ancient Greek word for the “Land of Silk”, symbolizing the East, sophistication and luxury. Inspired by the spirit of the Silk Road, SERES is committed to building a luxury automotive brand that brings Chinese innovation to the global stage.

About AITO

The AITO brand is built on the philosophy of “Intelligence Redefining Luxury.” With outstanding intelligent features and refined luxury quality, it has become the top-selling Chinese luxury car brand in China in 2025. The AITO lineup surpassed one million cumulative deliveries in just 46 months, setting a new delivery speed record for Chinese luxury new energy vehicle brands.

Media Contact:
Contact Person: Zhao Yan Yu
Email: yanyu.zhao@seres.cn

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/b17f348a-cfaf-4bd4-86f2-00d3f9c3e522

https://www.globenewswire.com/NewsRoom/AttachmentNg/dbfee1b4-b163-400f-837a-49dc0d42f375

12:15 London, 14:15 Helsinki, 30 October 2026 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR)

Production report Q3 2026

Afarak Group’s overall production for the first three quarters of 2026 has increased by 17.9% when compared to the same period in 2025. This growth was primarily driven by the South African mines, which are now operating steadily following extensive and continuous preparation work.

			Q3/2026	Q3/2025	Change	YTD 2026	YTD 2025	Change	FY 2025
	Speciality Alloys	mt	23,385	23,952	-2.4%	73,808	80,107	-7.9%	105,432
	Processing	mt	3,233	6,039	-46.5%	16,996	21,966	-22.6%	27,626
	Mining	mt	20,152	17,913	12.5%	56,812	58,141	-2.3%	77,806
	South African mines	mt	89,733	28,932	210.3%	183,369	138,114	32.8%	173,451
	Mining	mt	89,733	28,932	210.3%	183,369	138,114	32.8%	173,451

Processing

• Processing volumes decreased by 46.5% in Q3 2026 compared to same quarter last year, driven by a strategic initiative to optimise inventory levels.

Mining

• The South African mining activity almost tripled (up 210.3%) YoY in Q3 2026.  This surge heavily drove YTD production, resulting in a 32.8% increase over the same period last year.

• The Turkish mining operations maintained steady growth, with an increase of 12.5% in Q3 2026 when compared to Q3 2025.

Outlook for Q4 2026

Demand and Price Trends:

The demand for Cr Ore has recently regressed, due to oversupply in China. The substantial hike in freight cost and the falling market prices have a significant impact on the profit margins.

LC FeCR consumption and pricing is slowly picking up from a very low level in the European market. The US market is doing much better, due to a healthy demand from the aeronautical sector. High freight costs from India and China are currently discouraging large imports.

Challenges and Opportunities:

The strengthening of USD helps to improve the results, along with the effect of CBAM and the introduction of a mandatory product liability and recall insurance, for all the ferrochrome products.

Helsinki, 30 October 2026

AFARAK GROUP SE

Board of Directors

For additional information, please contact:

Afarak Group SE

Guy Konsbruck, CEO, +356 2122 1566, guy.konsbruck@afarak.com

Financial reports and other investor information are available on the Company’s website: www.afarak.com.

Afarak Group is a specialist alloy producer focused on delivering sustainable growth with a Speciality Alloys business in southern Europe and a FerroAlloys business in South Africa. The Company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK).

Distribution:
NASDAQ Helsinki
London Stock Exchange
Main media

www.afarak.com

• Collaboration brings together Canon’s Alphenix interventional fluoroscopy system and Stereotaxis’ GenesisX robotic technology
• Technologies will be presented at TCT 2026 in the Canon booth

TUSTIN, Calif. and ST. LOUIS, Oct. 30, 2026 (GLOBE NEWSWIRE) — Canon Medical Systems USA, a leader in innovative diagnostic imaging solutions, and Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced a technology compatibility and commercial collaboration to pair Canon Medical’s Alphenix interventional imaging platform with Stereotaxis’ GenesisX Robotic Magnetic Navigation system.

Canon and Stereotaxis are collaborating to offer their respective systems in a compatible fashion alongside each other. Canon Medical’s Alphenix platform provides advanced imaging, visualization, dose-management and workflow capabilities for interventional cardiology, with flexible configurations designed to support complex procedures. GenesisX enables precise robotic navigation of interventional catheters, with a semi-mobile architecture designed to facilitate adoption broadly within existing catheterization labs without any construction.

The combination of these two advanced technologies aims to expand access to next-generation robotic electrophysiology technology. The collaboration will enable the companies to enhance customer knowledge regarding their respective technologies, providing healthcare organizations greater flexibility when planning advanced robotic electrophysiology labs. The companies will further explore opportunities for Alphenix and GenesisX to improve workflow and introduce advanced capabilities in electrophysiology. Such efforts may apply beyond electrophysiology to support the advancement of robotic technology in interventional cardiology and neurointerventional procedures.

“As electrophysiology continues to evolve, customers need the flexibility to build advanced labs around the technologies and workflows that best meet their needs,” said Tsuneo “Neo” Imai, President & CEO of Canon Medical Systems USA. “Our collaboration with Stereotaxis reinforces Canon Medical’s commitment to customer choice and creates an exciting opportunity to bring Alphenix imaging together with Robotic Magnetic Navigation.”

“We are delighted to collaborate with Canon Medical to bring together two complementary technologies for the modern EP lab,” said David Fischel, Chairman and CEO of Stereotaxis. “More tightly coordinating the delivery of advanced interventional imaging and robotic technologies offers hospitals an exciting approach to building their robotic electrophysiology programs.”

About Canon Medical Systems USA, Inc.
Canon Medical Systems USA, Inc. markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, molecular imaging, ultrasound, X-ray, and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website: https://us.medical.canon/

About Canon Medical Group
Canon Medical Group provides a comprehensive range of medical imaging solutions, including CT, diagnostic and interventional X-ray, MRI, ultrasound, service solutions, and advanced Healthcare IT. In line with Canon Medical Group’s continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to equip healthcare professionals with innovative solutions that enhance clinical performance, safety, comfort, and outcomes—helping deliver better health opportunities for patients worldwide. We invest in research and product development that directly addresses the real clinical, operational, and business needs of our customers. By improving accessibility, enabling cross-platform integration, and supporting patient-centered care pathways, we aim to deliver solutions that are both meaningful and impactful. Working hand in hand with our medical, academic, and research partners, we build relationships founded on transparency, trust, and respect. Together, we strive to create industry-leading innovations that improve patient outcomes and enrich quality of life for communities around the world. https://global.medical.canon/

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts: David L. Fischel Chairman and Chief Executive Officer Kimberly Peery Chief Financial Officer 314-678-6100 Investors@Stereotaxis.com

Canon Medical Systems USA Contacts: Olivia Duarte Director of Corporate Communications (800) 421-1968

NEW ALBANY, Ohio, Oct. 30, 2026 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Tuesday, November 24, 2026, at 8:30 a.m. ET. A press release detailing the company’s third quarter results is expected to be issued shortly after 7:30 a.m. ET.   In addition, a presentation of the third quarter results will be available on the company’s website at approximately 7:30 a.m. ET.

Conference Call:	To access the conference call by phone, participants will need to register to obtain a dial-in phone number and an access code. Register for the call using this link.
Webcast:	To listen to a live webcast of the call, please visit corporate.abercrombie.com/investors/news-and-events/events/ and click the link to the webcast.
Replay:	A replay of the webcast will be available at corporate.abercrombie.com/investors shortly after the call ends and will be archived for one year.

Further information is available at corporate.abercrombie.com. Important information may be disseminated initially or exclusively via the website: investors should consult the site to access this information.

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co. (NYSE: ANF) is a global, digitally led omnichannel specialty retailer of apparel and accessories catering to kids through millennials with assortments curated for their specific lifestyle needs.

The company operates a family of brands, including Abercrombie brands and Hollister brands, each sharing a commitment to offer products of enduring quality and exceptional comfort that support global customers on their journey to being and becoming who they are. Abercrombie & Fitch Co. operates approximately 850 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites abercrombie.com, abercrombiekids.com, and hollisterco.com.

Investor Contact:		Media Contact:
Mo Gupta		Mackenzie Gusweiler
Abercrombie & Fitch Co.		Abercrombie & Fitch Co.
(614) 283-6751		(614) 283-6192
Investor_Relations@anfcorp.com		Public_Relations@anfcorp.com

Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27

Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 registrational UPSTREAM oMG trial; first patient dosing anticipated in 1H27

Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren’s disease

Cash and investment balance of $481.6 million expected to provide runway into early 2029

BOSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) —  Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We ended the third quarter with UPSTREAM MG fully enrolled and three registrational clinical trials advancing across the MG spectrum and Sjögren’s disease,” said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. “The final two-year Phase 3 TELIGAN results in IgAN from China add another important layer to the clinical evidence for telitacicept, demonstrating durable preservation of kidney function and sustained proteinuria reduction through 104 weeks. Taken together with the growing experience across autoimmune diseases, these data continue to strengthen our view of what dual BAFF and APRIL inhibition may be able to achieve over time. As we approach 2027, our focus is on generating the evidence that can define the role of telitacicept and establish Vor as a leading company in immunology.”

Program Highlights

Telitacicept: a potential best- and first-in-class dual BAFF/APRIL inhibitor in development for generalized myasthenia gravis (gMG) and primary Sjögren’s disease (SjD)

Generalized Myasthenia Gravis

• UPSTREAM MG
  • Enrollment complete in the global randomized, double-blind, placebo-controlled Phase 3 registrational trial with an open-label extension assessing the efficacy and safety of telitacicept in gMG
  • Topline data anticipated in 1H 2027

Primary Sjögren’s Disease

• UPSTREAM SjD
  • Enrollment ongoing in global randomized, double-blind, placebo-controlled Phase 3 registrational trial assessing the efficacy and safety of telitacicept in SjD

Corporate Updates

• Completed enrollment in UPSTREAM MG, the global Phase 3 registrational trial evaluating telitacicept in gMG
• Announced plans to initiate UPSTREAM oMG, a global Phase 3 registrational trial evaluating telitacicept in ocular myasthenia gravis, with first patient dosing anticipated in the first half of 2027
• Presented new 48-week analyses from the Phase 3 trial of telitacicept in gMG, conducted in China by collaborator RemeGen, at the 2026 AANEM Annual Meeting, including sustained MSE data showing that 42.1% of treated participants achieved MSE over 48 weeks and spent approximately 83% of subsequent follow-up in MSE after first achievement
• Presented final two-year results from the Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, conducted in China by collaborator RemeGen, at the American Society of Nephrology (ASN) Kidney Week 2026, showing an annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo (p<0.001) and sustained proteinuria reductions through 104 weeks

Third Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities were $481.6 million as of September 30, 2026, which are projected to fund operations into early 2029.
• R&D expenses for the third quarter of 2026 were $34.5 million, compared to $14.1 million for the third quarter of 2025. The increase of $20.4 million was primarily due to increased spending for our new programs, telitacicept in gMG and SjD, as well as increased personnel-related expenses as our research and development headcount increased compared to the prior year period as we continue to increase R&D activities.
• General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2026 were $23.9 million, compared to $14.0 million for the third quarter of 2025. The increase of $9.9 million was primarily due to increases in personnel-related expenses and stock-based compensation compared to the prior year period as our headcount grew to support the Company’s increase in operational activity.
• Net Loss: Net loss for the third quarter of 2026 was $86.7 million, compared to a $812.7 million net loss for the third quarter of 2025. The decrease in loss of $726.0 million was primarily due to the change in fair value of the outstanding liability-classified warrants in the third quarter of 2026 compared to the change in fair value recognized in the third quarter of 2025.

About Telitacicept
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL – two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), generalized myasthenia gravis (gMG), IgA nephropathy (IgAN), and Sjögren’s disease (SjD).

Vor Bio is advancing global development programs across major autoimmune indications, including a global Phase 3 trial in gMG and SjD, to support potential regulatory approvals in the United States, Europe, and Japan.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “design,” “expect,” “initiate,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “project,” “should,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding telitacicept’s potential as a first-in-class and best-in-class BAFF/APRIL therapy for gMG and SjD; the potential benefits of the dual BAFF and APRIL inhibition; our plan to generate the evidence that can define the role of telitacicept and establish Vor as a leading company in immunology; Vor Bio’s projected cash runway; Vor Bio’s development and commercialization plans for telitacicept, including the pursuit of potential regulatory approvals in the United States, Europe, and Japan, having topline data from the UPSTREAM MG trial and dosing the first patient in the UPSTREAM oMG trial in the first half of 2027; and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including that results from the TELIGAN trial, which RemeGen conducted solely in China, may not be predictive of results in other populations or in our ongoing or future clinical trials, and that the FDA and other regulators outside China may not accept data generated in China; that results of earlier clinical trials or analyses may not be predictive of future results, and that data presented at medical meetings may change following additional analysis or peer review; the risk of unexpected adverse events or safety findings; that conditional approvals in China may be withdrawn or not converted to full approval; our reliance on RemeGen, including for clinical data and the supply of telitacicept, and our ability to maintain our license with RemeGen; competition from other therapies, including other BAFF and/or APRIL inhibitors; that the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines; and possible limitations of financial and other resources. The clinical trial results described in this press release are based on information reported by RemeGen; Vor Bio has not independently verified these data. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Statements regarding Vor Bio’s cash runway do not indicate when or if Vor Bio may access the capital markets.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

CONTACT: Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) — Fervo Energy (“Fervo” or the “Company”) (NASDAQ: FRVO), a global pioneer of next-generation geothermal energy, today announced that it will release third quarter 2026 financial and operational results before the market opens on Monday, November 9, 2026. The Company will host a webcast and conference call that same day at 10:00 a.m. ET (9:00 a.m. CT) to discuss the results.

A live webcast of the conference call will be available in the “Events” section of the Company’s investor relations website at ir.fervoenergy.com. To participate in Q&A on the call, register here to receive the dial-in information and a unique PIN. A replay of the call will be available shortly after the live webcast’s conclusion.

ABOUT FERVO ENERGY

Fervo Energy is a modern power company built around one of the market’s most important needs: affordable, dependable new power supply. Through the large-scale deployment of enhanced geothermal systems, Fervo has established a repeatable, industrial approach to building utility-scale power. The company is transforming geothermal into a clean, reliable, cost-competitive solution designed to meet rising demand from AI hyperscalers, utilities, and a more electricity-intensive economy. For more information, visit www.fervoenergy.com.

Forward-Looking Statements

This announcement contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, are forward-looking statements. When used in this announcement, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Fervo believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Fervo’s control. Accordingly, forward-looking statements are not guarantees of future performance, and Fervo’s actual outcomes could differ materially from what Fervo has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: risks related to expanding our geothermal operations and accessing new markets; challenges in maintaining compliance with extensive environmental regulations and permitting requirements; uncertainties in forecasting future operational results and growth due to economic conditions and market demand; compliance with environmental regulations and climate change initiatives impacting operational costs; inherent risks in the geothermal industry, including potential operational disruptions and associated liabilities; the influence of consumer preferences, government policies, and competition on the demand for geothermal energy; risks associated with fluctuations in energy prices and material costs; dependence on a complex supply chain and successful maintenance of our geothermal infrastructure; financial performance influenced by fluctuations in interest rates, capital availability, and other market conditions; capacity actually constructed or for which we enter power purchase agreements under non-binding agreements, like the Geothermal Framework Agreement; exposure to legal proceedings and claims arising from our business operations; protecting our brand reputation and facing potential negative public perception; negative public perception and political opposition impacting our ability to secure regulatory approvals and market acceptance; the successful and timely execution of our growth strategy, with risks of delays or failures; reliance on key personnel and the potential impact of labor costs and workforce challenges; heavy reliance on technology systems and potential cybersecurity threats; global economic and political conditions affecting our operations, supply chain, and customer demand; the risk that our estimates of capacity potential and heat initially in place are inaccurate or that we are unable to produce quantities of electrical energy commensurate with such estimates; and other risks and uncertainties, including those set forth under “Risk Factors” in Fervo’s Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission (the “SEC”) on May 11, 2026, and Fervo’s other filings with the SEC.

In light of these factors, the events anticipated by Fervo’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Fervo operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. Fervo cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this announcement or, if earlier, as of the date they were made. Fervo does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Contacts

Investor Relations
investor.relations@fervoenergy.com

V2 Communications for Fervo Energy
fervo@v2comms.com

ICR, Inc.
Fervo@icrinc.com

GREENWICH, Conn., Oct. 30, 2026 (GLOBE NEWSWIRE) — Oxford Square Capital Corp. (NasdaqGS: OXSQ) (NasdaqGS: OXSQG) (NasdaqGS: OXSQH) (the “Company,” “we,” “us” or “our”) announced today its financial results and related information for the quarter ended September 30, 2026.

• On October 28, 2026, our Board of Directors declared the following distributions on our common stock:

Month Ending	Record Date	Payment Date	Amount Per Share
January 31, 2027	January 15, 2027	January 29, 2027	$0.015
February 28, 2027	February 12, 2027	February 26, 2027	$0.015
March 31, 2027	March 17, 2027	March 31, 2027	$0.015

• Net asset value (“NAV”) per share as of September 30, 2026, stood at $1.21, compared with a NAV per share on June 30, 2026 of $1.29.
• Net investment income (“NII”) was approximately $4.9 million, or $0.04 per share, for the quarter ended September 30, 2026, compared with approximately $5.1 million, or $0.05 per share, for the quarter ended June 30, 2026.
• Total investment income for the quarter ended September 30, 2026 amounted to approximately $9.9 million, compared with approximately $9.4 million for the quarter ended June 30, 2026.
  • For the quarter ended September 30, 2026 we recorded investment income from our portfolio as follows:
    • $5.6 million from our debt investments;
    • $3.6 million from our CLO equity investments; and
    • $0.6 million from other income.
• Our total expenses for the quarter ended September 30, 2026 were approximately $5.0 million, compared with total expenses of approximately $4.3 million for the quarter ended June 30, 2026.
• As of September 30, 2026, the following metrics applied (note that none of these metrics represented a total return to shareholders):
  • The weighted average yield of our debt investments was 15.0% at current cost, compared with 14.9% as of June 30, 2026;
  • The weighted average effective yield of our CLO equity investments at current cost was 8.1%, which was approximately the same as of June 30, 2026;
  • The weighted average cash distribution yield of our cash income producing senior secured note investments at current cost was 8.1%, compared with 8.0% as of June 30, 2026; and
  • The weighted average cash distribution yield of our cash income producing CLO equity investments at current cost was 12.0%, compared with 12.4% as of June 30, 2026.
• For the quarter ended September 30, 2026, we recorded a net increase in net assets resulting from operations of approximately $1.6 million, consisting of:
  • NII of approximately $4.9 million;
  • Net realized losses of approximately $11.3 million; and
  • Net unrealized appreciation of approximately $7.9 million. 
• During the third quarter of 2026, our investment activity consisted of purchases of approximately $20.8 million and repayments of approximately $10.3 million. No sales were made during the quarter.
• Our weighted average credit rating was 2.2 based on total fair value and 2.3 based on total principal amount as of September 30, 2026, compared with a weighted average credit rating of 2.1 based on total fair value and 2.2 based on total principal amount as of June 30, 2026.
• As of September 30, 2026, our preferred equity investments in one of our portfolio companies were on non-accrual status, which had an aggregate fair value of approximately $6.8 million.
• For the quarter ended September 30, 2026, we issued a total of approximately 14.1 million shares of common stock pursuant to an “at-the-market” offering. After deducting the sales agent’s commissions and offering expenses, this resulted in net proceeds of approximately $19.4 million. As of September 30, 2026, we had approximately 120.0 million shares of common stock outstanding.

We will hold a conference call to discuss third quarter results today, Friday, October 30^th, 2026 at 9:00 AM ET. The toll-free dial-in number is 1-800-715-9871, access code number 5885175. There will be a recording available for 30 days. If you are interested in hearing the recording, please dial 1-800-770-2030. The replay passcode is 5885175#.

A presentation containing further detail regarding our quarterly results of operations has been posted under the Investor Relations section of our website at www.oxfordsquarecapital.com.

OXFORD SQUARE CAPITAL CORP.
STATEMENTS OF ASSETS AND LIABILITIES
		September 30, 2026				December 31, 2025
		(Unaudited)
ASSETS
Non-affiliated/non-control investments (cost: $380,691,717 and $390,403,599, respectively)		$	255,081,298			$	251,731,345
Controlled affiliate investment (cost: $5,000,000 and $0, respectively)			5,000,000				—
Cash equivalents (cost: $42,822,297 and $51,236,068)			42,822,297				51,236,068
Cash			689,210				698,579
Interest and distributions receivable			2,327,310				2,002,161
Other assets			1,157,126				1,070,958
Total assets		$	307,077,241			$	306,739,111
LIABILITIES
Notes payable – 5.50% Unsecured Notes, net of deferred issuance costs of $707,710 and $996,075, respectively			79,792,290				79,503,925
Notes payable – 7.75% Unsecured Notes, net of deferred issuance costs of $2,193,859 and $2,621,662, respectively			72,556,141				72,128,338
Securities purchased, not settled			5,834,523				5,944,969
Accrued interest payable			1,703,438				1,703,438
Base Fee and Net Investment Income Incentive Fee payable to affiliate			1,029,470				1,036,058
Accrued expenses			782,346				1,017,581
Total liabilities			161,698,208				161,334,309
NET ASSETS
Common stock, $0.01 par value, 300,000,000 shares authorized; 120,048,538 and 86,060,964 shares issued and outstanding, respectively			1,200,485				860,610
Capital in excess of par value			574,172,265				523,040,484
Total distributable earnings/(accumulated losses)			(429,993,717	)			(378,496,292	)
Total net assets			145,379,033				145,404,802
Total liabilities and net assets		$	307,077,241			$	306,739,111
Net asset value per common share		$	1.21			$	1.69

OXFORD SQUARE CAPITAL CORP.
STATEMENTS OF OPERATIONS (Unaudited)
		Three Months Ended September 30, 2026				Three Months Ended September 30, 2025				Nine Months Ended September 30, 2026				Nine Months Ended September 30, 2025
INVESTMENT INCOME
From non-affiliated/non-control investments:
Interest income – debt investments(1)		$	4,688,883			$	4,456,544			$	13,543,422			$	13,511,141
Interest income – debt investments – payment-in-kind (“PIK”)(1)			944,668				705,534				2,628,190				2,271,142
Income from securitization vehicles and investments			3,623,609				4,298,003				10,356,553				12,109,128
Other income			649,471				779,852				1,723,237				2,031,753
Total investment income from non-affiliated/non-control investments			9,906,631				10,239,933				28,251,402				29,923,164
Total investment income			9,906,631				10,239,933				28,251,402				29,923,164
EXPENSES
Interest expense			2,796,502				2,559,400				8,381,637				6,447,732
Base Fee			1,029,470				1,053,566				2,981,744				3,148,663
Professional fees			364,954				351,582				1,153,068				1,119,285
Compensation expense			297,901				254,096				776,994				721,969
General and administrative			504,166				357,769				1,175,575				1,073,155
Excise tax			—				104,778				(419,110	)			250,179
Total expenses before incentive fees			4,992,993				4,681,191				14,049,908				12,760,983
Net Investment Income Incentive Fees			—				—				—				—
Total incentive fees			—				—				—				—
Total expenses			4,992,993				4,681,191				14,049,908				12,760,983
Net investment income			4,913,638				5,558,742				14,201,494				17,162,181
NET CHANGE IN UNREALIZED APPRECIATION/(DEPRECIATION) AND NET REALIZED LOSSES ON INVESTMENT TRANSACTIONS
Net change in unrealized appreciation/(depreciation) on investments:
Non-affiliated/non-control investments			7,926,223				(7,497,769	)			13,061,835				(8,311,530	)
Total net change in unrealized appreciation/(depreciation) on investments			7,926,223				(7,497,769	)			13,061,835				(8,311,530	)
Net realized losses:
Non-affiliated/non-control investments			(11,275,801	)			(32,797	)			(47,230,540	)			(14,512,854	)
Extinguishment of debt			—				(120,339	)			—				(166,118	)
Total net realized losses			(11,275,801	)			(153,136	)			(47,230,540	)			(14,678,972	)
Net change in unrealized and realized losses			(3,349,578	)			(7,650,905	)			(34,168,705	)			(22,990,502	)
Net increase/(decrease) in net assets resulting from operations		$	1,564,060			$	(2,092,163	)		$	(19,967,211	)		$	(5,828,321	)
Net increase in net assets resulting from net investment income per common share (Basic and Diluted):		$	0.04			$	0.07			$	0.14			$	0.23
Net increase/(decrease) in net assets resulting from operations per common share (Basic and Diluted):		$	0.01			$	(0.03	)		$	(0.20	)		$	(0.08	)
Weighted average shares of common stock outstanding (Basic and Diluted):			111,280,920				79,362,161				99,695,097				74,231,017
Distributions per share		$	0.105			$	0.105			$	0.315			$	0.315

_______________________

(1) Change in prior period was made to conform to the current period presentation.

FINANCIAL HIGHLIGHTS (Unaudited)

Financial highlights for the three and nine months ended September 30, 2026 and 2025, respectively, are as follows:

		Three Months Ended September 30, 2026				Three Months Ended September 30, 2025				Nine Months Ended September 30, 2026				Nine Months Ended September 30, 2025
Per Share Data
Net asset value at beginning of period		$	1.29			$	2.06			$	1.69			$	2.30
Net investment income(1)			0.04				0.07				0.14				0.23
Net realized and unrealized losses(2)			(0.02	)			(0.08	)			(0.34	)			(0.30	)
Net increase/(decrease) in net asset value from operations			0.02				(0.01	)			(0.20	)			(0.07	)
Distributions per share from net investment income(3)			(0.11	)			(0.11	)			(0.32	)			(0.31	)
Tax return of capital distributions(3)			—				—				—				—
Total distributions(3)			(0.11	)			(0.11	)			(0.32	)			(0.31	)
Effect of shares issued			0.01				0.01				0.04				0.03
Net asset value at end of period		$	1.21			$	1.95			$	1.21			$	1.95
Per share market value at beginning of period		$	1.32			$	2.23			$	1.76			$	2.44
Per share market value at end of period		$	1.28			$	1.59			$	1.28			$	1.59
Total return based on market value(4)			4.94	%			(24.74	)%			(9.99	)%			(24.97	)%
Total return based on net asset value(5)			1.94	%			(0.24	)%			(9.76	)%			(1.52	)%
Shares outstanding at end of period			120,048,538				81,669,408				120,048,538				81,669,408
Ratios/Supplemental Data
Net assets at end of period (000’s)		$	145,379			$	158,955			$	145,379			$	158,955
Average net assets (000’s)		$	138,603			$	159,073			$	133,325			$	154,918
Ratio of expenses to average net assets(6)			14.41	%			11.77	%			14.16	%			11.00	%
Ratio of expenses, excluding interest expense, to average net assets(6)			6.34	%			5.34	%			5.77	%			5.45	%
Ratio of net investment income to average net assets(6)			14.18	%			13.98	%			14.10	%			14.76	%
Portfolio turnover rate(7)			4.06	%			12.70	%			4.51	%			20.42	%

____________
(1) Represents per share net investment income for the period, based upon weighted average shares outstanding.
(2) Net realized and unrealized losses include rounding adjustments to reconcile change in net asset value per share.
(3) Management monitors available taxable earnings, including net investment income and realized capital gains, to determine if a tax return of capital may occur for the year. To the extent the Company’s taxable earnings fall below the total amount of the Company’s distributions for that fiscal year, a portion of those distributions may be deemed a tax return of capital to the Company’s stockholders. The ultimate tax character of the Company’s earnings cannot be determined until tax returns are prepared after the end of the fiscal year. The amounts and sources of distributions reported are only estimates (based on an average of the reported tax character historically) and are not being provided for U.S. tax reporting purposes. For each of the three-month periods ended September 30, 2026 and 2025, distributions were $0.105 per share and are presented as $0.11 per share due to rounding. For the nine months ended September 30, 2026, distributions were $0.315 per share and are presented as $0.32 per share due to rounding. For the nine months ended September 30, 2025, distributions were $0.315 per share and are presented as $0.31 per share due to rounding.
(4) Total return based on market value equals the increase or decrease of ending market value over beginning market value, plus distributions, divided by the beginning market value, assuming distribution reinvestment prices obtained under the Company’s distribution reinvestment plan. Total return is not annualized.
(5) Total return based on net asset value equals the increase or decrease of ending net asset value over beginning net asset value, plus distributions, divided by the beginning net asset value. Total return is not annualized.
(6) Annualized and adjusted for one-time excise tax reversals.
(7) Portfolio turnover rate is calculated using the lesser of the investment sales and debt repayments or investment purchases, over the average of the total investments at fair value.

About Oxford Square Capital Corp.

Oxford Square Capital Corp. is a publicly-traded business development company principally investing in syndicated bank loans and, to a lesser extent, debt and equity tranches of collateralized loan obligation (“CLO”) vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Contact:
Bruce Rubin
203-983-5280

Move supports the company’s long-term growth strategy and goal of pursuing a listing on the Nasdaq Stock Exchange

NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) — Umbra Companies, Inc. (UCIX) today announced its decision to move its corporate offices from Colorado to New York City. The relocation represents an important step in the company’s long-term growth strategy as it works to expand its visibility, strengthen relationships across the real estate industry, and pursue its goal of becoming listed on the Nasdaq Stock Exchange, subject to meeting all applicable requirements and receiving approval from Nasdaq.

“New York City is one of the world’s most influential centers for real estate, finance, investment, and business,” said Rohn Monroe, Chief Executive Officer. “Relocating our offices to New York City places Umbra Companies in a dynamic environment that aligns with our ambitions and provides greater opportunities to connect with investors, development partners, financial professionals, and other key stakeholders.”

Strategic Benefits of the Relocation

As a real estate development company, Umbra Companies expects its presence in New York City to provide several strategic advantages, including:

• Greater access to capital and financial networks: New York City is home to a broad community of investment firms, lenders, analysts, financial advisers, and capital-market professionals who may support the company’s future growth initiatives.
• Enhanced industry connections: Establishing a presence in a major real estate market can create additional opportunities to engage with developers, property owners, architects, contractors, brokers, institutional investors, and other potential partners.
• Increased corporate visibility: A New York City office can strengthen Umbra Companies’ profile among investors, business media, industry organizations, and other audiences interested in real estate development and capital markets.
• Stronger investor-relations opportunities: Proximity to the financial community may make it easier to participate in meetings, conferences, presentations, and other activities designed to communicate the company’s strategy and objectives.
• Improved access to talent and expertise: New York City offers a deep and diverse pool of professionals with experience in real estate, finance, development, legal services, marketing, and corporate operations.
• Alignment with public-company ambitions: The relocation supports Umbra Companies’ efforts to build the corporate infrastructure, visibility, and relationships that may be important as the company evaluates its path toward a potential Nasdaq listing.

Building a More Visible Corporate Presence

The move is expected to help Umbra Companies develop a more visible and accessible corporate presence in one of the world’s leading business centers. By operating closer to important real estate and financial networks, the company intends to broaden awareness of its business, improve stakeholder engagement, and position itself for future opportunities.

While the company is excited about the potential benefits of the relocation, a Nasdaq listing is not assured and would depend on Umbra Companies satisfying Nasdaq’s listing standards, completing the applicable review process, and obtaining approval. The company will continue to assess its corporate, financial, and operational requirements as it pursues its long-term objectives.

About Umbra Companies, Inc.

Umbra Companies, Inc. (UCIX) is a real estate development company focused on building its business and creating long-term value through strategic growth. The company’s planned relocation to New York City reflects its commitment to expanding its visibility, strengthening industry relationships, and pursuing future opportunities in the real estate and capital markets.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding the anticipated benefits of relocating to New York City, the company’s growth strategy, increased visibility, and its goal of pursuing a potential Nasdaq listing. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially from those anticipated, and there can be no assurance that the expected benefits will be realized or that Umbra Companies will satisfy the requirements for or receive approval for a Nasdaq listing.

CONTACT: Contact
Umbra Companies Inc.
14 Wall St. 20th Floor
New York, NY 10005
O: +1.833.833.2913
Pr@umbraucix.com  
Website: umbracompaniesinc.com